The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica
Open accessAbstract
Neuromyelitis optica (NMO) is a disabling autoimmune astrocytopathy characterized by typically severe and recurrent attacks of optic neuritis and longitudinally extensive myelitis. Until recently, NMO was considered an acute aggressive variant of multiple sclerosis (MS), despite the fact that early studies postulated that NMO and MS may be two distinct diseases with a common clinical picture. With the discovery of a highly specific serum autoantibody (NMO‐IgG), Lennon and colleagues provided the first unequivocal evidence distinguishing NMO from MS and other central nervous system (CNS) inflammatory demyelinating disorders. The target antigen of NMO‐IgG was confirmed to be aquaporin‐4 (AQP4), the most abundant water channel protein in the CNS, mainly expressed on astrocytic foot processes at the blood–brain barrier, subpial and subependymal regions. Pathological studies demonstrated that astrocytes were selectively targeted in NMO as evidenced by the extensive loss of immunoreactivities for the astrocytic proteins, AQP4 and glial fibrillary acidic protein (GFAP), as well as perivascular deposition of immunoglobulins and activation of complement even within lesions with a relative preservation of myelin. In support of these pathological findings, GFAP levels in the cerebrospinal fluid (CSF) during acute NMO exacerbations were found to be remarkably elevated in contrast to MS where CSF‐GFAP levels did not substantially differ from controls. Additionally, recent experimental studies showed that AQP4 antibody is pathogenic, resulting in selective astrocyte destruction and dysfunction in vitro, ex vivo and in vivo. These findings strongly suggest that NMO is an autoimmune astrocytopathy where damage to astrocytes exceeds both myelin and neuronal damage. This chapter will review recent neuropathological studies that have provided novel insights into the pathogenic mechanisms, cellular targets, as well as the spectrum of tissue damage in NMO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Self-citationWalport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441406 · Cited by 2,927
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Self-citationThe clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Reactive astrocytes: cellular and molecular cues to biological function
Ridet, J. L., Privat, A., Malhotra, S. K., & Gage, F. H. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01139-9 · Cited by 1,766
Nielsen, S., Arnulf Nagelhus, E., Amiry-Moghaddam, M., Bourque, C., Agre, P., & Petter Ottersen, O. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-01-00171.1997 · Cited by 1,442
Cited by
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Self-citationBlood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
CNS inflammation and neurodegeneration
Chitnis, T., & Weiner, H. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90609 · Cited by 470
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Carnero Contentti, E., & Correale, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02249-1 · Cited by 338
Neuromyelitis Spectrum Disorders
Weinshenker, B. G., & Wingerchuk, D. M. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.12.014 · Cited by 286
Zamvil, S. S., & Slavin, A. J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000062 · Cited by 276
CNS remyelination and inflammation: From basic mechanisms to therapeutic opportunities
Franklin, R. J. M., & Simons, M. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.023 · Cited by 184
Chen, A., Akinyemi, R. O., Hase, Y., Firbank, M. J., Ndung’u, M. N., Foster, V., Craggs, L. J. L., Washida, K., Okamoto, Y., Thomas, A. J., et al. (2016) · Brain · doi:10.1093/brain/awv328 · Cited by 172
Atypical inflammatory demyelinating syndromes of the CNS
Hardy, T. A., Reddel, S. W., Barnett, M. H., Palace, J., Lucchinetti, C. F., & Weinshenker, B. G. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30043-6 · Cited by 161
Self-citationGarg, N., Reddel, S. W., Miller, D. H., Chataway, J., Riminton, D. S., Barnett, Y., Masters, L., Barnett, M. H., & Hardy, T. A. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309649 · Cited by 76
The contribution of neuropathology to multiple sclerosis research
Lassmann, H. (2022) · European Journal of Neurology · doi:10.1111/ene.15360 · Cited by 55
Pamphlett, R., & Kum Jew, S. (2018) · BioMetals · doi:10.1007/s10534-018-0124-4 · Cited by 53
Hofer, L. S., Ramberger, M., Gredler, V., Pescoller, A. S., Rostásy, K., Sospedra, M., Hegen, H., Berger, T., Lutterotti, A., & Reindl, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01188 · Cited by 30
Jiang, S., Li, X., Li, Y., Chang, Z., Yuan, M., Zhang, Y., Zhu, H., Xiu, Y., Cong, H., Yin, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg5116 · Cited by 30
T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity
Sagan, S. A., Moinfar, Z., Moseley, C. E., Dandekar, R., Spencer, C. M., Verkman, A. S., Ottersen, O. P., Sobel, R. A., Sidney, J., Sette, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306572120 · Cited by 25
Yick, L.-W., Ma, O. K.-F., Chan, E. Y.-Y., Yau, K. X., Kwan, J. S.-C., & Chan, K.-H. (2023) · JCI Insight · doi:10.1172/jci.insight.161003 · Cited by 21
“Following AQP4 immunization, we observed that AQP4 and GFAP losses coincided with C5b-9 deposition.”
InfluentialKlyscz, P., Vigiser, I., Solorza Buenrostro, G., Motamedi, S., Leutloff, C. J., Schindler, P., Schmitz‐Hübsch, T., Paul, F., Zimmermann, H. G., & Oertel, F. C. (2025) · European Journal of Neurology · doi:10.1111/ene.70038 · Cited by 7
Metadata
- Authors
- Lucchinetti, C. F., Guo, Y., Popescu, B. F. G., Fujihara, K., Itoyama, Y., & Misu, T.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2013-12-18
- Volume
- 24
- Issue
- 1
- Pages
- 83-97
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W2119987649
- Cited by
- 414
- References
- 104
- FWCI
- 15.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.